Hausärztliche Leitlinie Hypertonie – Therapie Der ... - Arztbibliothek

99 Schneeweiss S, Hasford J, Göttler M, Hoffmann A,
Riethling AK, Avorn J. Admissions caused by adverse drug
events to internal medicine and emergency departments in
hospitals: a longitudinal population-based study. Eur J Clin
Pharmacol 2002; 58 (4): 285-291
100 Schneider D, Richling F. Checkliste Arzneimittel A-Z.
Stuttgart: Georg Thieme Verlag, 2004
101 Scriven AJ et al. Changes in blood pressure and plasma
catecholamines caused by tyramine and cold exposure. J
Cardiovasc Pharmacol 1984; 6: 954-960 [IIa]
102 SHEP Cooperative Research Group. Prevention of heart
failure by antihypertensive drug treatment in older persons
with isolated systolic hypertension. JAMA 1997; 278: 212-
216
103 SHEP Cooperative Research Group. Prevention of stroke
by antihypertensive drug treatment in older persons with
isolated systolic hypertension. Final results of the Systolic
Hypertension in the Elderly Program (SHEP). JAMA 1991;
265: 3255-3264
104 Sidney C, Smith Jr. Risk-Reduction Therapy: The
challenge to change. Circulation 1996; 93: 2205-2221
105 Siscovick D, Raghunathan T, Psaty B et al. Diuretic
therapy for hypertension and the risk of primary cardiac
arrest. N Engl J Med 1994: 1852-1857
106 Song F, Eastwood AJ, Gilbody S et al. Publication and
related biases. Health Technology Assessment 2000; 4:
1-115
107 Stamler J. Epidemiological findings on body mass and
blood pressure in adults. Ann Epidemiol 1991; 1: 347-362
108 Steassen J, Fagard R, Thijs L et al for the Systolic
Hypertension in Europe (Syst-Eur) Trial Investigators.
Randomised double blind comparision of placebo and
active treatment for older patients with isolated systolic
hypertension. The Lancet 1997; 350: 757-764 [Ib]
109 Swedberg K, Kjekshus J, Snapinn S for the CONSENSUS
Investigators. Long-term survival in severe heart failure in
patients treated with enalapril. Eur Heart J 1999, 20: 136-
139
110 Systolic Hypertension in Europe Trial Investigators.
Predicting cardiovascular risk using conventional vs.
ambulatory blood pressure in older patients with systolic
hypertension. JAMA 1999; 282: 539-546
111 Szasz JJ et al. Effects on distension of the bladder and
contraction of sphincters on blood pressure. BMJ 1967; ii:
208-210 [IV]
� Zitierte Literatur
Literatur
112 Thamm M. Blutdruck in Deutschland – Zustandsbeschreibung
und Trends. Gesundheitswesen 1999; 61, Sonderheft
2: 590-593
113 The ALLHAT Officers and Coordinators for the ALLHAT
Collaborative Research Group. Major outcomes in highrisk
hypertensive patients randomizes to angiotensinconverting
enzyme inhibitor or calcium channel blocker vs.
diuretic. JAMA 2002; 288: 2981-2997
114 The EUCLID Study Group. Randomised placebo-controlled
trial of lisinopril in normotensive patients with insulindependent
diabetes and normoalbuminuria or
microalbuminuria. Lancet 1997; 349: 1787-1792
115 The Heart Outcomes Prevention Evaluation Study
Investigators. Effects of an Angiotensin-Converting-
Enzyme Inhibitor, Ramipril, on cardiovascular events in
high-risk patients. N Engl J Med 2000; 342: 145-153 [Ib]
116 The Holland Interuniversity Nifedipine/Metoprolol Trial
(HINT) Research Group. Early treatment of unstable
angina in the coronary care unit: a randomised, double
blind, placebo controlled comparison of recurrent
ischaemia in patients treated with nifedipine or metoprolol
or both. Br Heart J 1986; 56: 400-413
117 The SOLVD Investigators. Effects of enalapril on mortality
and the development of heart failure in asymptomatic
patients with reduced left ventricular ejection fractions. N
Engl J Med 1992; 327: 685-691
118 Thürmann PA. Geschlechtsspezifische Unterschiede bei
der Phamakokinetik und -dynamik von Arzneimitteln.
Bundesgesundheitsblatt Gesundheitsforschung
Gesundheitsschutz 2005; 48 (5): 536-540
119 Thürmann PA. Arzneimittelanwendung bei Frauen: "Off-
Label"? Psychopharmakotherapie 2007; 14 (6): 237-242
120 Thürmann PA. Geschlechtspezifische Unterschiede bei
Arzneimitteln. Ther Umsch 2007; 64 (6): 325-329
121 Thürmann PA. Warum gibt es geschlechtsspezifische
Unterschiede in der Wirkung von Arzneimitteln? Berliner
Ärzte 2009; 17-20
122 Thürmann PA, Haack S, Werner U et al. Tolerability of
beta-blockers metabolized via cytochrome P450 2D6 is
sex-dependent. Clin Pharmacol Ther 2006; 80 (5): 551-553
123 Thürmann P, Janhsen K, Werner U et al. Geschlechtsspezifische
Unterschiede bei unerwünschten Arzneimittelwirkungen
im Zusammenhang mit Diuretika (15. Jahrestagung
der GAA). Update: 11.2008. Verfügbar unter:
http://www.egms.de/en/meetings/gaa2008/08gaa11.shtml
Hausärztliche Leitlinie »Therapie der Hypertonie« Version 3.00 I 03. Februar 2010
41